The Medicines Company Reports Third-Quarter 2017 Business and Financial Results

25 Oct 2017

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities.

“We made significant clinical and strategic progress during the third quarter,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We aggressively advanced start-up work for the inclisiran Phase III clinical program, preparing investigational sites–which began screening patients in September–and manufacturing double-blind-packaged drug supply, and are pleased to announce that dosing of patients in the Phase III LDL-C lowering program will commence next week. We remain confident that all trials comprising the inclisiran LDL-C lowering program will commence before year-end. Turning to our process to monetize our Infectious Disease Business (ID Business), we continue to expect to announce a transaction to divest the business before the end of the year. In the meantime, independent of that transaction, we are finalizing plans to significantly restructure the remainder of The Medicines Company. We anticipate that the restructuring, which we intend to substantially implement within the next 45 days, will reduce headcount to less than 60 people at The Medicines Company (excluding the ID Business), significantly reducing go-forward annual operating expenses. As indicated in our strategic plans previously disclosed, we believe that the restructuring, when taken together with the anticipated disposition of our ID Business, will provide the Company with a strong financial position from which to aggressively advance the inclisiran development program to anticipated readout of final data from the Phase III LDL-C lowering trials in the second half of 2019. We expect to provide further information regarding the restructuring plan and its implementation in our third quarter Form 10-Q.”

Third-Quarter 2017 Highlights

Inclisiran (PCSK9 synthesis inhibitor)

  • On August 28, 2017, new, one-year data from the ORION-1 Phase II study of inclisiran was presented in the “Hot Line – Late-Breaking Clinical Trials 2” session at the European Society of Cardiology (ESC) Congress 2017. Efficacy data presented reaffirmed inclisiran’s significant LDL-C lowering effects following a starting dose of 300 mg given on Day-1 and Day-90, after which the mean LDL-C reduction was 56% at Day-150 and 51% at Day-180. For the subsequent six-month period – from Day-90 to Day-270 – the time-averaged LDL-C reduction was 51%, with minimum intra-patient variability over time (all comparisons to placebo P <0.0001). These robust data underscore the selection of a six-monthly maintenance dose of 300 mg in the inclisiran Phase III clinical program. With completion of one-year follow-up, safety data for inclisiran from the Phase II ORION-1 study now include 370 subject-years of observation, including at least 300 subject-years of inclisiran effects. As in prior analyses, no material safety issues were observed on inclisiran, which continued to demonstrate an adverse event profile similar to placebo. There were no deaths or serious adverse events during the extended observation period. In particular, in spite of the prolonged LDL-C lowering effects of inclisiran, there were no investigational drug-related elevations of liver enzymes and no neuropathy, change in renal function, thrombocytopenia or anti-drug antibodies during extended follow-up, or at any earlier time periods in the ORION-1 study.

VABOMERE

  • On August 29, 2017, the U.S. Food and Drug Administration (FDA) approved VABOMERE (meropenem-vaborbactam) for injection for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae – Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae species complex.
  • At IDWeek 2017 in October, the Company presented new data on VABOMERE, including results from the landmark TANGO II study of VABOMERE versus “best available therapy” (BAT) in the treatment of suspected or documented infections due to carbapenem-resistant Enterobacteriaceae (CRE). Highlights from the posters on the TANGO II study included:
        <ul>
          <li class="bwlistitemmargb">
            VABOMERE was associated with a higher clinical cure versus BAT in 
            patients with a baseline organism that was CRE (mCRE-MITT 
            population) at both end-of-therapy (EOT) (VABOMERE 64.3% vs. BAT 
            33.3%; p=0.04) and test-of-cure (TOC) (VABOMERE 57.1% vs. BAT 
            26.7%; p=0.04). In immunocompromised patients, VABOMERE was also 
            associated with a higher clinical cure versus BAT at EOT (VABOMERE 
            60% vs. BAT 12.5%; p&lt;0.01), and a relative mortality benefit of 
            46.7%.
          </li>
          <li class="bwlistitemmargb">
            In further exploratory analyses, VABOMERE was associated with a 
            relative mortality benefit of 84% (p = 0.03) compared to BAT when 
            excluding patients with previous antibiotic failures.
          </li>
        </ul>
      </li>
    </ul>
    <table cellspacing="0" class="bwtablemarginb">
      <tbody><tr>
        <td colspan="10">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl" colspan="10">
          <p class="bwcellpmargin">
            <b>Sensitivity Analysis of Clinical Cure at TOC and All-Cause 
            Mortality at Day 28 Across All</b><br><b>Infection Types 
            (mCRE-MITT) Excluding Prior Antibiotic Failure</b>
          </p>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          <b>M-V </b><br><b>N=19 </b><br><b>n (%)</b>
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          <b>BAT </b><br><b>N=15 </b><br><b>n (%)</b>
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          <p class="bwcellpmargin">
            <b>Absolute Difference</b><br><b>(95% CI)</b>
          </p>
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          <i><b>P </b></i><b>value</b>
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          <p class="bwcellpmargin">
            <b>Relative</b><br><b>Difference</b>
          </p>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignm bwalignl bwsinglebottom">
          Patients with All Infection Types
        </td>
        <td class="bwsinglebottom" colspan="9">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignm bwalignl bwsinglebottom">
          Clinical Cure at TOC
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          13 (68.4)
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          4 (26.7)
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwvertalignm bwalignc bwsinglebottom">
          41.8 (11.1 to 72.4)
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          0.008
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          156.2
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignm bwalignl bwsinglebottom">
          Day-28 All-cause Mortality
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          1 (5.3)
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          5 (33.3)
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwvertalignm bwalignc bwsinglebottom">
          -28.1 (-54.0 to -2.2)
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          0.03
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom">
          -84.1
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td>
        </td>
        <td>
          &nbsp;
        </td>
        <td>
        </td>
        <td>
          &nbsp;
        </td>
        <td>
        </td>
        <td>
          &nbsp;
        </td>
        <td>
        </td>
        <td>
          &nbsp;
        </td>
        <td>
        </td>
      </tr>
    </tbody></table>
    <ul class="bwmarginl1">
      <li class="bwlistitemmargb">
        VABOMERE was associated with decreased nephrotoxicity and 
        significantly fewer treatment-related adverse events versus BAT.
      </li>
      <li class="bwlistitemmargb">
        An analysis using the composite endpoints of clinical failure or 
        nephrotoxicity demonstrated a risk-benefit profile favoring VABOMERE 
        versus BAT (VABOMERE 32.1% vs BAT 80.0% (95% CI: ?74.5 to ?21.2; <i>P</i>&lt; 
        0.001)).
      </li>
    </ul>
    <ul>
      <li class="bwlistitemmargb">
        In July 2017, the Company announced randomization in the TANGO II 
        trial was stopped early following a recommendation by the TANGO II 
        independent Data and Safety Monitoring Board (DSMB) based on an 
        analysis of 72 patients, including 43 patients with microbiologically 
        evaluable CRE infections of blood, lung, urinary tract and abdominal 
        organs. The DSMB concluded that a risk-benefit analysis of available 
        data no longer supported randomization of additional patients to the 
        best available therapy comparator arm.
      </li>
      <li class="bwlistitemmargb">
        VABOMERE is now available for pharmacies to order through wholesalers 
        and usual distribution channels.
      </li>
    </ul>
    <p>
      <b>Third-Quarter 2017 Financial Summary from Continuing Operations</b><br>Worldwide 
      net revenue was $16.9 million in the third quarter of 2017 compared to 
      $37.6 million in the third quarter of 2016. Included in total net 
      revenue for the third quarter of 2017 and 2016 was $7.9 million and 
      $28.9 million, respectively, of total Angiomax revenue, including both 
      royalty revenues derived from the gross profit on authorized generic 
      sales of Angiomax® (bivalirudin) by Sandoz, Inc. and worldwide 
      Angiomax®/Angiox® (bivalirudin) net product sales. Other products 
      recorded aggregate sales of $9.0 million in the third quarter of 2017 
      compared to $6.7 million in the third quarter of 2016. Among these other 
      products, Minocin® (minocycline) for Injection and Orbactiv® 
      (oritavancin) recorded sales of $9.0 million in the third quarter of 
      2017 compared to $6.5 million in the third quarter of 2016, an increase 
      of 38%, predominantly driven by an increase in Orbactiv (oritavancin) 
      revenue of 57%, from $4.3 million in the third quarter of 2016 to $6.8 
      million in the third quarter of 2017. The third quarter of 2016 also 
      included $2.0 million of sales related to the divested non-core 
      cardiovascular products.
    </p>
    <p>
      On a GAAP basis, net loss from continuing operations in the third 
      quarter of 2017 was $30.2 million, or $0.42 per share, compared to $86.4 
      million, or $1.23 per share, in the third quarter of 2016. On a non-GAAP 
      basis, adjusted net loss<sup> (1)</sup> from continuing operations in 
      the third quarter of 2017 was $86.3 million, or $1.19<sup>(1)</sup> per 
      share, compared to $44.8 million, or $0.64<sup>(1)</sup> per share, in 
      the third quarter of 2016.
    </p>
    <p>
      <b>Third-Quarter 2016 Financial Summary from Discontinued Operations</b><br>In 
      the first quarter of 2016, the Company completed the divestiture of its 
      hemostasis products for an upfront payment of $174.1 million, and 
      potential milestone payments of up to an additional $235.0 million, in 
      the aggregate, following the achievement of certain specified net sales 
      milestones. Net income from discontinued operations in the third quarter 
      of 2016 was $0.1 million.
    </p>
    <p>
      <b>First Nine Months 2017 Financial Summary from Continuing Operations</b><br>Worldwide 
      net revenue was $59.8 million in the first nine months of 2017 compared 
      to $142.6 million in the first nine months of 2016. Included in total 
      net revenue for the first nine months of 2017 and 2016 was $35.9 million 
      and $104.9 million, respectively, of total Angiomax revenue, including 
      both royalty revenues derived from the gross profit on authorized 
      generic sales of Angiomax (bivalirudin) by Sandoz, Inc. and worldwide 
      Angiomax/Angiox (bivalirudin) net product sales. Other products, 
      including Minocin (minocycline) for Injection and Orbactiv 
      (oritavancin), recorded aggregate sales of $23.9 million in the first 
      nine months of 2017 compared to $17.4 million in the first nine months 
      of 2016. The first nine months of 2016 also included $20.3 million of 
      sales related to the divested non-core cardiovascular products.
    </p>
    <p>
      On a GAAP basis, net loss from continuing operations in the first nine 
      months of 2017 was $530.1 million, or $7.39 per share, compared to net 
      income from continuing operations of $5.1 million, or $0.07 per share, 
      in the first nine months of 2016. Included in net loss from continuing 
      operations for the first nine months of 2017 were net charges of 
      approximately $277.0 million associated with the discontinuation and 
      market withdrawal of Ionsys (fentanyl iontophoretic transdermal system) 
      in the U.S. market, and $27.3 million associated with the 
      discontinuation of the clinical development program for MDCO-700, our 
      investigational anesthetic agent. On a non-GAAP basis, adjusted net loss<sup> 
      (1)</sup> from continuing operations in the first nine months of 2017 
      was $234.5 million, or $3.27<sup>(1)</sup> per share, compared to $164.2 
      million, or $2.35<sup>(1)</sup> per share, in the first nine months of 
      2016.
    </p>
    <p>
      <b>First Nine Months 2016 Financial Summary from Discontinued Operations</b><br>Net 
      loss from discontinued operations in the first nine months of 2016 was 
      $1.4 million, or $0.02 per share.
    </p>
    <p class="bwmarginl1">
      <sup>(1)</sup> Adjusted net loss and adjusted loss per share from 
      continuing operations are non-GAAP financial performance measures with 
      no standardized definitions under U.S. GAAP. For further information and 
      a detailed reconciliation, refer to the “Non-GAAP Financial Performance 
      Measures” and “Reconciliations of GAAP to Adjusted Net Loss and Adjusted 
      Loss per Share” sections of this press release.
    </p>
    <p>
      At September&nbsp;30, 2017, the Company had a total of $208.9 million in cash 
      and cash equivalents and available for sale securities.
    </p>
    <p>
      <b>Third-Quarter 2017 Conference Call and Webcast Information</b><br>The 
      Company will host a conference call and webcast today, October 25, 2017, 
      at 8:30 a.m., Eastern Daylight Time, to discuss its third-quarter 2017 
      financial results and provide clinical and operational updates. The 
      dial-in information to access the call is as follows:
    </p>
    <p class="bwmarginl1">
      U.S./Canada: (877) 359-9508<br>International: (224) 357-2393<br>Conference 
      ID: 9194649
    </p>
    <p>
      A taped replay of the conference call will be available from 11:30 a.m., 
      Eastern Daylight Time, today until 11:30 a.m., Eastern Daylight Time, on 
      November 1, 2017. The replay may be accessed as follows:
    </p>
    <p class="bwmarginl1">
      U.S./Canada: (855) 859-2056<br>International: (404) 537-3406<br>Conference 
      ID: 9194649
    </p>
    <p>
      The webcast can be accessed in the Investors section of <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.themedicinescompany.com%2Finvestors%2Fevents&amp;esheet=51704844&amp;newsitemid=20171025005540&amp;lan=en-US&amp;anchor=The+Medicines+Company&amp;index=1&amp;md5=23a3d06fb3239d303d032bc1a4beda1f" rel="nofollow">The 
      Medicines Company</a> website. A replay of the webcast will also be 
      available.
    </p>
    <p>
      <b>About VABOMERE</b>™<br>VABOMERE™ (meropenem and vaborbactam) is 
      indicated for the treatment of patients 18 years of age and older with 
      complicated urinary tract infections (cUTI), including pyelonephritis, 
      caused by the following susceptible microorganisms: <i>Escherichia coli</i>, 
      <i>Klebsiella pneumoniae</i>, and <i>Enterobacter cloacae species</i> 
      complex.
    </p>
    <p>
      To reduce the development of drug-resistant bacteria and maintain the 
      effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should 
      be used only to treat or prevent infections that are proven or strongly 
      suspected to be caused by susceptible bacteria.
    </p>
    <p>
      For more information on VABOMERE, including its important safety 
      information and package insert, please see <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vabomere.com%2F&amp;esheet=51704844&amp;newsitemid=20171025005540&amp;lan=en-US&amp;anchor=www.vabomere.com&amp;index=2&amp;md5=dbe9031667083298db32d172b00b3cf7" rel="nofollow">www.vabomere.com</a>.
    </p>
    <p>
      <b>About Inclisiran</b><br>Inclisiran (formerly known as PCSK9si and 
      ALN-PCSsc) is an investigational GalNAc-conjugated RNAi therapeutic 
      targeting PCSK9 – a genetically validated protein regulator of LDL 
      receptor metabolism – being developed for the treatment of 
      hypercholesterolemia. In contrast to anti-PCSK9 monoclonal antibodies 
      (MAbs) that bind to PCSK9 in blood, inclisiran is a first-in-class 
      investigational medicine that acts by turning off PCSK9 synthesis in the 
      liver.
    </p>
    <p>
      The Medicines Company and Alnylam Pharmaceuticals, Inc. are 
      collaborating in the advancement of inclisiran pursuant to their 2013 
      agreement. Under the terms of the agreement, Alnylam completed certain 
      pre-clinical studies and the Phase I clinical study, with The Medicines 
      Company leading and funding the development of inclisiran from Phase II 
      forward, as well as potential commercialization.
    </p>
    <p>
      <b>About The&nbsp;Medicines Company</b><br>The Medicines Company is a 
      biopharmaceutical company driven by an overriding purpose – to save 
      lives, alleviate suffering and contribute to the economics of 
      healthcare. The Company’s mission is to create transformational 
      solutions to address the most pressing healthcare needs facing patients, 
      physicians and providers in serious infectious disease care and 
      cardiovascular care. The Company is headquartered in Parsippany, New 
      Jersey, with a global innovation center in California.
    </p>
    <p>
      <b>Forward-Looking Statements</b><br>Statements contained in this 
      press release that are not purely historical may be deemed to be 
      forward-looking statements for purposes of the safe harbor provisions 
      under The Private Securities Litigation Reform Act of 1995. Without 
      limiting the foregoing, the words "believes," "anticipates," "plans," 
      "expects" and similar expressions, including the Company's preliminary 
      financial results, are intended to identify forward-looking statements. 
      These forward-looking statements involve known and unknown risks and 
      uncertainties that may cause the Company's actual results, levels of 
      activity, performance or achievements to be materially different from 
      those expressed or implied by these forward-looking statements. 
      Important factors that may cause or contribute to such differences 
      include whether the Company's product candidates will advance in the 
      clinical trials process on a timely basis or at all, or succeed in 
      achieving their specified endpoints; whether the Company will make 
      regulatory submissions for product candidates on a timely basis; whether 
      its regulatory submissions will receive approvals from regulatory 
      agencies on a timely basis or at all; whether the Company’s ongoing and 
      planned commercial launches will be successful; the extent of the 
      commercial success of our products; the Company's ability to penetrate 
      foreign markets; whether physicians, patients and other key decision 
      makers will accept clinical trial results; whether the Company can 
      protect its intellectual property; whether the Company will be able to 
      raise additional capital on favorable terms or at all when needed; and 
      such other factors as are set forth in the risk factors detailed from 
      time to time in the Company's periodic reports and registration 
      statements filed with the Securities and Exchange Commission, including, 
      without limitation, the risk factors detailed in the Company's Quarterly 
      Report on Form 10-Q filed with the SEC on August 9, 2017, which are 
      incorporated herein by reference. The Company specifically disclaims any 
      obligation to update these forward-looking statements.
    </p>
    <p>
      <b>NON-GAAP FINANCIAL PERFORMANCE MEASURES</b><br>In addition to 
      financial information prepared in accordance with U.S. GAAP, this press 
      release also contains adjusted net loss and adjusted loss per share from 
      continuing operations attributable to The Medicines Company. The Company 
      believes these measures provide investors and management with 
      supplemental information relating to operating performance and trends 
      that facilitate comparisons between periods and with respect to 
      projected information.
    </p>
    <p>
      Adjusted net loss from continuing operations excludes share-based 
      compensation expense, amortization of acquired intangible assets, asset 
      impairment charges, inventory adjustments, restructuring charges, 
      charges associated with product discontinuance, milestone payments, 
      changes in contingent purchase price, expenses incurred for certain 
      transactions, non-cash interest expense, gain on sale of assets, loss on 
      repurchase of debt and net loss tax adjustments. The Company believes 
      these non-GAAP financial measures help indicate underlying trends in the 
      Company’s business and are important in comparing current results with 
      prior period results and understanding projected operating performance. 
      Non-GAAP financial measures provide the Company and its investors with 
      an indication of the Company’s baseline performance before items that 
      are considered by the Company not to be reflective of the Company’s 
      ongoing results. See the attached Reconciliations of GAAP to Adjusted 
      Net Loss and Adjusted Loss per Share for explanations of the amounts 
      excluded and included to arrive at adjusted net loss and adjusted loss 
      per share amounts for the three- and nine-month periods ended September 
      30, 2017 and 2016.
    </p>
    <p>
      These adjusted measures are non-GAAP and should be considered in 
      addition to, but not as a substitute for, the information prepared in 
      accordance with U.S. GAAP. The Company strongly encourages investors to 
      review its consolidated financial statements and publicly-filed reports 
      in their entirety and cautions investors that the non-GAAP measures used 
      by the Company may differ from similar measures used by other companies, 
      even when similar terms are used to identify such measures.
    </p>
    <p>
    </p>
    <table cellspacing="0" class="bwtablemarginb">
      <tbody><tr>
        <td colspan="16">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc" colspan="16">
          <p class="bwcellpmargin">
            <b>THE MEDICINES COMPANY</b><br><b>CONSOLIDATED STATEMENTS OF 
            OPERATIONS</b><br><b>UNAUDITED</b><br><i>(In thousands, except 
            per share amounts)</i>
          </p>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="7">
          <b>Three Months Ended</b><br><b>September 30,</b>
        </td>
        <td>
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="7">
          <b>Nine Months Ended</b><br><b>September 30,</b>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2017</b>
        </td>
        <td>
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2016</b>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2017</b>
        </td>
        <td>
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2016</b>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Net product revenues
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          10,935
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          18,843
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          38,135
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          80,542
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb1 bwvertalignb bwalignl">
          Royalty revenues
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          5,936
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          18,756
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          21,694
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          62,094
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Total net revenues
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          16,871
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          37,599
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          59,829
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          142,636
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Operating expenses:
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Cost of product revenues
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          9,601
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          20,777
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          39,436
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          54,804
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Asset impairment charges
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          329,097
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Research and development
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          45,838
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          23,537
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          117,337
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          94,595
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwpadb1 bwvertalignb bwalignl">
          Selling, general and administrative
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          47,198
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          69,022
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          159,980
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          242,478
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwpadb1 bwvertalignb bwalignl">
          Total operating expenses
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          102,637
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          113,336
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          645,850
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          391,877
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Loss from operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (85,766
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (75,737
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (586,021
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (249,241
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Co-promotion and license income
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          769
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          757
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          2,283
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          3,073
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Gain on sale of assets
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          288,301
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Loss on extinguishment of debt
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (5,380
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Interest expense
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (11,886
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (12,089
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (36,898
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (32,198
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwpadb1 bwvertalignb bwalignl">
          Other (loss) income
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          71
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          865
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          916
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          741
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          (Loss) income from continuing operations before income taxes
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (96,812
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (86,204
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (619,720
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          5,296
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwpadb1 bwvertalignb bwalignl">
          Benefit (provision) for income taxes
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          66,637
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (163
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          89,607
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (220
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb1 bwvertalignb bwalignl">
          Net (loss) income from continuing operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (30,175
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (86,367
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (530,113
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          5,076
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb1 bwvertalignb bwalignl">
          Income (loss) from discontinued operations, net of tax
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          96
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (1,390
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Net (loss) income
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (30,175
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (86,271
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (530,113
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          3,686
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb1 bwvertalignb bwalignl">
          Net loss attributable to non-controlling interest
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          13
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          50
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb3 bwvertalignb bwalignl">
          Net (loss) income attributable to The Medicines Company
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (30,175
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (86,258
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (530,113
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          3,736
        </td>
        <td class="bwdoublebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Amounts attributable to The Medicines Company:
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Net (loss) income from continuing operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (30,175
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (86,354
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (530,113
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          5,126
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb1 bwvertalignb bwalignl">
          Income (loss) from discontinued operations, net of tax
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          96
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (1,390
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb3 bwvertalignb bwalignl">
          Net (loss) income attributable to The Medicines Company
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (30,175
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (86,258
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (530,113
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          3,736
        </td>
        <td class="bwdoublebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Basic (loss) earnings per common share attributable to The Medicines 
          Company:
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          (Loss) earnings from continuing operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (0.42
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (1.23
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (7.39
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          0.07
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwpadb1 bwvertalignb bwalignl">
          Loss from discontinued operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (0.02
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwpadb3 bwvertalignb bwalignl">
          <p class="bwcellpmargin">
            Basic (loss) earnings per share
          </p>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (0.42
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (1.23
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (7.39
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          0.05
        </td>
        <td class="bwdoublebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Diluted (loss) earnings per common share attributable to The 
          Medicines Company:
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          (Loss) earnings from continuing operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (0.42
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (1.23
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (7.39
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          0.07
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwpadb1 bwvertalignb bwalignl">
          Loss from discontinued operations
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (0.02
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwpadb3 bwvertalignb bwalignl">
          Diluted (loss) earnings per share
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (0.42
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (1.23
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (7.39
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          0.05
        </td>
        <td class="bwdoublebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Weighted average number of common shares outstanding:
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Basic
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          72,286
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          70,194
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          71,763
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          69,711
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Diluted
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          72,286
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          70,194
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          71,763
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          72,920
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
          &nbsp;
        </td>
      </tr>
    </tbody></table>
    <p>
    </p>
    <table cellspacing="0" class="bwtablemarginb">
      <tbody><tr>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
          &nbsp;
        </td>
        <td colspan="2">
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignt bwalignc" colspan="6">
          <p class="bwcellpmargin">
            <b>THE MEDICINES COMPANY</b><br><b>BALANCE SHEET ITEMS</b><br><b>UNAUDITED</b><br><i>(In 
            thousands)</i>
          </p>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="2">
          <b>September 30, 2017</b>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="2">
          <b>December 31, 2016</b>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Cash and cash equivalents
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          166,734
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          541,835
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Available for sale securities
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          42,168
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          —
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Total assets
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          1,006,980
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          1,705,211
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Convertible senior notes (due 2022 and 2023)
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          642,655
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          677,333
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          The Medicines Company stockholders' equity
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          188,055
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          652,501
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td>
        </td>
        <td>
        </td>
        <td>
        </td>
        <td>
        </td>
        <td>
          &nbsp;
        </td>
      </tr>
    </tbody></table>
    <p>
    </p>
    <table cellspacing="0" class="bwtablemarginb">
      <tbody><tr>
        <td>
        </td>
        <td>
        </td>
        <td colspan="7">
        </td>
        <td>
          &nbsp;
        </td>
        <td colspan="7">
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignt bwalignc" colspan="17">
          <p class="bwcellpmargin">
            <b>THE MEDICINES COMPANY</b><br><b>RECONCILIATIONS OF GAAP TO 
            ADJUSTED NET LOSS<br>AND ADJUSTED LOSS PER SHARE</b><br><b>UNAUDITED</b><br><i>(In 
            thousands, except per share amounts)</i>
          </p>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="7">
          <b>Three Months Ended</b><br><b>September 30,</b>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="7">
          <b>Nine Months Ended</b><br><b>September 30,</b>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2017</b>
        </td>
        <td>
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2016</b>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2017</b>
        </td>
        <td>
          &nbsp;
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom" colspan="3">
          <b>2016</b>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          <p class="bwcellpmargin">
            Net (loss) income from continuing operations attributable to The<br>Medicines 
            Company - GAAP
          </p>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (30,175
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (86,354
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (530,113
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          5,126
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Before tax adjustments:
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Cost of product revenues:
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Share-based compensation expense
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(1)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          205
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          195
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          613
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          691
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Amortization of acquired intangible assets
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(2)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          3,105
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          6,469
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          11,557
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          19,319
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Inventory adjustments
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(3)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (348
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          6,460
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (3,531
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,248
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Restructuring charges
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(4)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          18
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          108
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (48
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          383
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Market withdrawal of Ionsys
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(5)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          8,458
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Asset impairment charges
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Market withdrawal of Ionsys
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(5)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          264,097
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Discontinuance of MDCO 700
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(6)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          65,000
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Research and development:
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Share-based compensation expense
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(1)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,332
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          916
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          3,888
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          2,923
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Restructuring charges
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(4)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (36
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          91
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          359
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,451
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Milestone payments
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(7)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          11,000
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Market withdrawal of Ionsys
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(5)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,032
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Selling, general and administrative:
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Share-based compensation expense
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(1)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          6,341
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          6,849
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          19,579
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          20,555
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Restructuring charges
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(4)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,110
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,447
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          1,007
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          14,445
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Changes in contingent purchase price
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(8)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (7,673
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          12,393
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          4,234
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          14,346
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Market withdrawal of Ionsys
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(5)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          3,434
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Discontinuance of MDCO 700
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(6)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (14,701
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Expenses incurred for certain transactions
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(9)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          7,887
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Other:
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Non-cash interest expense
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(10)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          6,504
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          6,622
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          20,326
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          19,392
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Gain on sale of assets
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(11)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          (288,301
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl6 bwvertalignb bwalignl">
          Loss on extinguishment of debt
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(12)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          —
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          5,380
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb1 bwvertalignb bwalignl">
          Net loss tax adjustments
        </td>
        <td class="bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr">
          <sup>(13)</sup>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (66,713
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          1
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          (89,702
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom" colspan="2">
          —
        </td>
        <td class="bwsinglebottom">
          &nbsp;
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwpadb3 bwvertalignb bwalignl">
          Net loss attributable to The Medicines Company - Adjusted
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (86,330
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (44,803
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (234,511
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwdoublebottom">
          (164,155
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwdoublebottom">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          <p class="bwcellpmargin">
            Net loss per share attributable to The Medicines Company - Adjusted
          </p>
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Basic
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (1.19
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (0.64
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (3.27
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (2.35
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Diluted
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (1.19
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (0.64
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (3.27
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          $
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr">
          (2.35
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl">
          )
        </td>
      </tr>
      <tr>
        <td class="bwpadl0 bwvertalignb bwalignl">
          Weighted average number of common shares outstanding:
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
        <td>
        </td>
        <td colspan="3">
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Basic
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          72,286
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          70,194
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          71,763
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          69,711
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td class="bwpadl3 bwvertalignb bwalignl">
          Diluted
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          72,286
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          70,194
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          71,763
        </td>
        <td>
        </td>
        <td>
        </td>
        <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr" colspan="2">
          69,711
        </td>
        <td>
        </td>
      </tr>
      <tr>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
        </td>
        <td>
        </td>
        <td colspan="2">
        </td>
        <td>
          &nbsp;
        </td>
      </tr>
    </tbody></table>
    <p>
      Explanation of Adjustments:
    </p>
    <p class="bwmarginl1">
      (1) Excludes share-based compensation of $7,878 and $7,960 for the three 
      months ended September 30, 2017 and 2016 and $24,080 and $24,169 for the 
      nine months ended September 30, 2017 and 2016 because these expenses are 
      substantially dependent on changes in the market price of the Company's 
      common stock.<br>(2) Excludes amortization of intangible assets 
      resulting from transactions with Targanta, Incline Therapeutics and 
      Rempex.<br>(3) Excludes all non-cash inventory adjustments. Prior year 
      balances revised to reflect all non-cash inventory adjustments for the 
      respective periods.<br>(4) Excludes restructuring charges for the 
      workforce reorganization related to the sale of the non-core 
      cardiovascular products.<br>(5) Excludes charges associated with the 
      voluntary discontinuation and withdrawal of Ionsys from the market in 
      the United States and cessation of related commercial activities.<br>(6) 
      Excludes costs associated with the decision to discontinue the MDCO-700 
      program.<br>(7) Excludes upfront and milestone payments for research 
      and development collaboration arrangements and manufacturing scale up 
      for MDCO-216.<br>(8) Excludes changes in fair value of the contingent 
      price related to the acquisitions of Targanta, Incline Therapeutics, 
      Rempex and Annovation.<br>(9) Excludes transaction costs related to 
      the sale of the Non-Core ACC Products.(10) Excludes non-cash interest 
      expense which is in excess of the actual interest expense paid on the 
      Convertible Senior Notes.<br>(11) Excludes gain on the sale of the 
      Non-Core ACC Products.<br>(12) Excludes loss on the repurchase of 
      $220.0 million in aggregate principal amount of the 2017 Notes.<br>(13) 
      Net loss tax adjustments reflect the estimated tax effect of the costs 
      associated with the decision to discontinue the MDCO-700 program and the 
      amortization of Vabomere IPR&amp;D.
    </p>
    <p>
      <i>In addition to the financial information prepared in accordance with 
      U.S. GAAP, this press release also contains adjusted financial measures 
      that the Company believes provide investors and management with 
      supplemental information relating to operating performance and trends 
      that facilitate comparisons between periods and with respect to 
      projected information.</i> <i>These adjusted measures should be 
      considered in addition to, but not as a substitute for, the information 
      prepared in accordance with U.S. GAAP.</i> <i>The Company strongly 
      encourages investors to review its consolidated financial statements and 
      publicly filed reports in their entirety and cautions investors that the 
      non-GAAP measures used by the Company may differ from similar measures 
      used by other companies, even when similar terms are used to identify 
      such measures.</i>
    </p>
    <p>
    </p>
    


    Contacts

    The Medicines Company
    Media
    Meg Langan, 973-290-6319
    Vice President
    margaret.langan@themedco.com
    or
    Investor Relations
    Krishna Gorti, M.D., 973-290-6122
    Vice President, Investor Relations
    krishna.gorti@themedco.com

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com